Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

8.3%

1 terminated out of 12 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

11Total
Not Applicable (3)
Early P 1 (3)
P 1 (2)
P 2 (3)

Trial Status

Recruiting4
Active Not Recruiting3
Not Yet Recruiting3
Unknown1
Terminated1

Clinical Trials (12)

Showing 12 of 12 trials
NCT04145115Phase 2Active Not Recruiting

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

NCT05592743Unknown

Vorasidenib Expanded Access Program

NCT07585851Early Phase 1Active Not RecruitingPrimary

Administration of Repurposed Ketoconazole in Glioma Patients

NCT07469735Not ApplicableNot Yet Recruiting

Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma

NCT05553041Early Phase 1Recruiting

18F-Fluciclovine PET-MRI in High-grade Glioma

NCT05717153Early Phase 1RecruitingPrimary

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

NCT06831461Not ApplicableRecruiting

Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors

NCT06492486Phase 2Not Yet RecruitingPrimary

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

NCT04910022Phase 1Active Not Recruiting

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

NCT06016452Phase 2RecruitingPrimary

A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma

NCT04341311Phase 1Terminated

Phase I Study of Marizomib + Panobinostat for Children With DIPG

NCT06093165Not ApplicableNot Yet Recruiting

RE-irradiation of Diffuse MIdline Glioma paTients

Showing all 12 trials

Research Network

Activity Timeline